CT 01 programme - Captor Therapeutics
Alternative Names: CPT-5170; CPT-6281; CT-01; CT-01 compounds; CT-01 project; Project CT-01Latest Information Update: 05 Jun 2023
At a glance
- Originator Captor Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Proteolysis
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Liver cancer
Most Recent Events
- 30 May 2023 Captor Therapeutics expects a Clinical Trial Application authorization for Liver cancer, in Q3 2023
- 12 Apr 2022 Pharmacodynamics data from preclinical studies in Liver cancer released by Captor Therapeutics
- 25 Jan 2022 CT 01 - Captor Therapeutics is available for licensing as of 13 Jan 2022. http://www.captortherapeutics.com/our-approach